Veteran Overmedication Prevention Act of 2017

Bill: 115-s-788
Sponsor: full_name: Sen. McCain, John [R-AZ]
Introduced: 2017-03-30
Policy area: Armed Forces and National Security
Subjects: Department of Veterans Affairs

Drug therapy

Drug trafficking and controlled substances

Drug, alcohol, tobacco use

Family relationships

Government employee pay, benefits, personnel management

Government information and archives

Government studies and investigations

Health facilities and institutions

Health information and medical records

Health personnel

Higher education

Hospital care

Marriage and family status

Medicaid

Medical education

Medical research

Medical tests and diagnostic methods

Mental health

Neurological disorders

Prescription drugs

Veterans' medical care
Latest action: action_date: 2017-03-30
text: Read twice and referred to the Committee on Veterans' Affairs.

Summaries:
action_date: 2017-03-30
action_desc: Introduced in Senate
text: <p><strong>Veteran Overmedication Prevention Act of 2017</strong></p> <p>This bill requires the Department of Veterans Affairs (VA) to contract with the National Academies of Sciences, Engineering, and Medicine (or another private, not-for-profit entity with comparable expertise) to review the deaths of all covered veterans who died by suicide during the last five years. A &quot;covered veteran&quot; is any veteran who received VA hospital care or medical services during the five-year period preceding the veteran's death.</p> <p>The review shall include:</p> <ul> <li>the total numbers of veterans who died by a violent death or by an accidental death during such period;</li> <li> each veteran's age, gender, race, and ethnicity;</li> <li>a list of medications and substances prescribed to such veterans, as annotated on toxicology reports;</li> <li>a summary of medical diagnoses by VA physicians that led to such prescriptions in cases of anxiety and depressive disorders;</li> <li>the number of instances in which such a veteran was concurrently on multiple medications prescribed by VA physicians;</li> <li>the number of such veterans who were not taking any VA-prescribed medication;</li> <li> the percentage of such veterans treated for anxiety or depressive disorders who received a non-medication first-line treatment compared to the percentage who received medication only;</li> <li> the number of instances in which a non-medication first-line treatment was attempted and deemed ineffective, which led to prescribing medication;</li> <li>descriptions of how the VA determines and updates clinical practice guidelines for prescribing medications and of VA efforts to maintain appropriate staffing levels for mental health professionals;</li> <li>the percentage of such veterans with combat experience or related trauma; </li> <li>identification of VA medical facilities with markedly high prescription rates and suicide rates for treated veterans;</li> <li> an analysis of VA programs that collaborate with state Medicaid agencies and the Centers for Medicare and Medicaid Services;</li> <li> an analysis of VA medical center collaboration with medical examiners' offices or local jurisdictions to determine veteran mortality and cause of death;</li> <li>identification of a best practice model to collect and share veteran death certificate data;</li> <li>an assessment of any apparent patterns based on the review; and</li> <li>recommendations to improve the safety and well-being of veterans. </li> </ul> <p>The VA shall ensure that such data is compiled in a manner that allows it to be analyzed across all data fields for purposes of informing and updating VA clinical practice guidelines.</p> <p>

tv_txt: II 115th CONGRESS 1st Session S. 788 IN THE SENATE OF THE UNITED STATES March 30, 2017 Mr. McCain introduced the following bill; which was read twice and referred to the Committee on Veterans' Affairs A BILL To direct the Secretary of Veterans Affairs to conduct an independent review of the deaths of certain veterans by suicide, and for other purposes.

1. Short title This Act may be cited as the Veteran Overmedication Prevention Act of 2017 . 2. Department of Veterans Affairs independent review of certain deaths of veterans by suicide (a) Review required (1) In general Not later than 90 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall seek to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine under which the National Academies shall conduct a review of the deaths of all covered veterans who died by suicide during the five-year period ending on the date of the enactment of this Act. (2) Alternate organization (A) In general If the Secretary is unable to enter into an agreement described in paragraph (1) with the National Academies of Sciences, Engineering, and Medicine on terms acceptable to the Secretary, the Secretary shall seek to enter into such an agreement with another appropriate organization that— (i) is not part of the Federal Government; (ii) operates as a not-for-profit entity; and (iii) has expertise and objectivity comparable to that of the National Academies of Sciences, Engineering, and Medicine. (B) Treatment If the Secretary enters into an agreement with another organization as described in paragraph (1), any reference in this section to the National Academies of Sciences, Engineering, and Medicine shall be treated as a reference to the other organization. (3) Elements The review required by paragraph (1) shall include the following: (A) The total number of covered veterans who died by suicide during the five-year period ending on the date of the enactment of this Act. (B) The total number of covered veterans who died by a violent death during such five-year period. (C) The total number of covered veterans who died by an accidental death during such five-year period. (D) A description of each covered veteran described in subparagraphs (A) through (C), including age, gender, race, and ethnicity. (E) A comprehensive list of prescribed medications and legal or illegal substances as annotated on toxicology reports of covered veterans described in subparagraphs (A) through (C), specifically listing any medications that carried a black box warning, were prescribed for off-label use, were psychotropic, or carried warnings that included suicidal ideation. (F) A summary of medical diagnoses by physicians of the Department of Veterans Affairs or physicians providing services to covered veterans through programs of the Department that led to the prescribing of medications referred to in subparagraph (E) in cases of post-traumatic stress disorder, traumatic brain injury, military sexual trauma, and other anxiety and depressive disorders. (G) The number of instances in which a covered veteran described in subparagraph (A), (B), or (C) was concurrently on multiple medications prescribed by physicians of the Department or physicians providing services to veterans through programs of the Department to treat post-traumatic stress disorder, traumatic brain injury, military sexual trauma, other anxiety and depressive disorders, or instances of comorbidity. (H) The number of covered veterans described in subparagraphs (A) through (C) who were not taking any medication prescribed by a physician of the Department or a physician providing services to veterans through a program of the Department. (I) With respect to the treatment of post-traumatic stress disorder, traumatic brain injury, military sexual trauma, or other anxiety and depressive disorders, the percentage of covered veterans described in subparagraphs (A) through (C) who received a non-medication first-line treatment compared to the percentage of such veterans who received medication only. (J) With respect to the treatment of covered veterans described in subparagraphs (A) through (C) for post-traumatic stress disorder, traumatic brain injury, military sexual trauma, or other anxiety and depressive disorders, the number of instances in which a non-medication first-line treatment (such as cognitive behavioral therapy) was attempted and determined to be ineffective for such a veteran, which subsequently led to the prescribing of a medication referred to in subparagraph (E). (K) A description and example of how the Department determines and continually updates the clinical practice guidelines governing the prescribing of medications. (L) A description of the efforts of the Department to maintain appropriate staffing levels for mental health professionals, such as mental health counselors, marriage and family therapists, and other appropriate counselors, including— (i) a description of any impediments to carry out the education, training, and hiring of mental health counselors and marriage and family therapists under section 7302(a) of title 38, United States Code; (ii) with respect to mental health counselors, marriage and family therapists, and other appropriate counselors, an identification of resolutions for— (I) any standardized credentialing discrepancies; and (II) any impediments to the development of an internship training program; (iii) an assessment of the development by the Department of hiring guidelines for mental health counselors, marriage and family therapists, and other appropriate counselors; and (iv) a description of how the Department— (I) identifies gaps in the supply of mental health professionals; and (II) determines successful staffing ratios for mental health professionals of the Department. (M) The percentage of covered veterans described in subparagraphs (A) through (C) with combat experience or trauma related to combat experience (including military sexual trauma, traumatic brain injury, and post-traumatic stress). (N) An identification of the medical facilities of the Department with markedly high prescription rates and suicide rates for veterans receiving treatment at those facilities. (O) An analysis, by State, of programs of the Department that collaborate with State Medicaid agencies and the Centers for Medicare and Medicaid Services, including the following: (i) An analysis of the sharing of prescription and behavioral health data for veterans. (ii) An analysis of whether Department staff check with State prescription drug monitoring programs before prescribing medications to veterans. (iii) A description of the procedures of the Department for coordinating with prescribers outside of the Department to ensure that veterans are not overprescribed. (iv) A description of actions that the Department takes when a veteran is determined to be overprescribed. (P) An analysis of the collaboration of medical centers of the Department with medical examiners’ offices or local jurisdictions to determine veteran mortality and cause of death. (Q) An identification and determination of a best practice model to collect and share veteran death certificate data between the Department of Veterans Affairs, the Department of Defense, States, and tribal entities. (R) An assessment of any patterns apparent to the National Academies of Sciences, Engineering, and Medicine based on the review conducted under paragraph (1). (S) Such recommendations for further action that would improve the safety and well-being of veterans as the National Academies of Sciences, Engineering, and Medicine determine appropriate. (4) Compilation of data (A) Form of compilation The Secretary of Veterans Affairs shall ensure that data compiled under paragraph (3) is compiled in a manner that allows it to be analyzed across all data fields for purposes of informing and updating clinical practice guidelines of the Department of Veterans Affairs. (B) Compilation of data regarding covered veterans In compiling data under paragraph (3) regarding covered veterans described in subparagraphs (A) through (C) of such paragraph, data regarding veterans described in each such subparagraph shall be compiled separately. (5) Completion of review and report The agreement entered into under paragraph (1) shall require that the National Academies of Sciences, Engineering, and Medicine complete the review under such paragraph and submit to the Secretary of Veterans Affairs a report containing the results of the review not later than 180 days after entering into the agreement. (b) Report Not later than 30 days after the completion by the National Academies of Sciences, Engineering, and Medicine of the review required under subsection (a), the Secretary of Veterans Affairs shall— (1) submit to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a report on the results of the review; and (2) make such report publicly available. (c) Definitions In this section: (1) The term black box warning means a warning displayed on the label of a prescription drug that is designed to call attention to the serious or life-threatening risk of the prescription drug. (2) The term covered veteran means a veteran who received hospital care or medical services furnished by the Department of Veterans Affairs during the five-year period preceding the death of the veteran. (3) The term first-line treatment means a potential intervention that has been evaluated and assigned a high score within clinical practice guidelines. (4) The term State means each of the several States, territories, and possessions of the United States, the District of Columbia, and the Commonwealth of Puerto Rico.